CSIMarket


An2 Therapeutics Inc   (ANTX)
Other Ticker:  
 


 

An2 Therapeutics Inc

ANTX's Financial Statements and Analysis



An2 Therapeutics Inc increased third quarter of 2023 net loss per share of $-0.65 compare to net loss per share of $-0.59 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.81 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -0.65 $  0 Mill
$-0.06     Unch.    



An2 Therapeutics Inc 's Revenue fell by 0 % in third quarter of 2023 (Sep 30 2023) year on year, to $0 million and declined by sequentially.


An2 Therapeutics Inc is

More on ANTX's Income Statement



An2 Therapeutics Inc 's in thethird quarter of 2023 recorded net loss of $-16.707 million, an increase from net loss of $-11.339 million in III. Quarter a year ago.

Sequentially net loss advanced

More on ANTX's Growth

An2 Therapeutics Inc Inventories
In Sep 30 2023 company's net cash and cash equivalents decreased by $-8 million


An2 Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period An2 Therapeutics Inc payed $ -1.71 cash per share, on a free-cash flow basis .

Book value grew by 20.38 % sequentially to $5.42 per share.
Tangible Book value grew to $ 5.42 per share from $ 4.50.

Company issued 6.15 million shares or 31.53 % in Sep 30 2023.


More on ANTX's Dividends

 Market Capitalization (Millions) 80
 Shares Outstanding (Millions) 26
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -60
 Cash Flow (TTM) (Millions $) 4
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




An2 Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period An2 Therapeutics Inc had negative $ -1.71 cash flow per share, on a free-cash flow basis .

Book value grew by 20.38 % sequentially to $5.42 per share.
Tangible Book value grew to $ 5.42 per share from $ 4.50.

Company issued 6.15 million shares or 31.53 % in Sep 30 2023.


More on ANTX's Balance Sheets

 Market Capitalization (Millions) 80
 Shares Outstanding (Millions) 26
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -60
 Cash Flow (TTM) (Millions $) 4
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about An2 Therapeutics Inc Earnings

ANTXs Reports Stable Revenue in Third Quarter of 2023, Demonstrating Strong Effort Despite Challenging Market Conditions



An2 Therapeutics Inc, a biotechnology company specializing in the development of therapeutic treatments, recently reported its financial results for the third quarter of 2023. The company experienced both positive and negative changes compared to the previous year. Additionally, its stock performance has fluctuated over the past trading days.
Financial Results:
An2 Therapeutics Inc's earnings per share (EPS) for the third quarter of 2023 showed a slight improvement, decreasing from $-0.81 per share in the previous reporting period to $-0.65 per share. However, this figure remains higher than the EPS of $-0.59 per share recorded a year ago. While the company has shown progress in reducing lo...

AN2 Therapeutics Inc Continues to Shine in Stock Market with Exciting Second Quarter Performance

Exciting Prospects in the Stock Market: ANTX Bolsters Confidence for Investors
The stock market is a fascinating arena, filled with ups and downs that keep investors on their toes. It's a platform where businesses strive to make their mark and create opportunities for potential shareholders. One such company that has caught the attention of many observers is ANTX, with its recent performance showcasing a promising trajectory.
During the period from April to June 30, 2023, ANTX experienced a modest increase in its shortfall per share. Although this may raise some eyebrows, it is worth noting that the shortfall per share only increased from $-0.53 to $-0.81 compared to a year ago. Additionally, it also...

1. AN2 Therapeutics Inc Reports Alarming Loss of $-0.79 per Share - Investors Should be Worried2. Lack of Revenue Growth Raises Concerns for AN2 Therapeutics Inc - Shareholders Left Unimpressed

Investors in An2 Therapeutics Inc have reason to be concerned about the recent financial results of the company, which showed significant losses from January to March 31, 2023. The company reported a loss of $-0.79 per share, a significant increase from the $-0.50 per share loss reported in the previous financial reporting period. This is indicative of a worrying trend for shareholders and should give cause for concern.
Furthermore, the revenue for January to March 31, 2023 remained unchanged at $0.00 million from the previous year, despite expectations of growth and improvement for the company. This lack of revenue growth over time is a red flag for investors, as it suggests that the company is struggli...


Date modified: 2023-11-12T11:34:49+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com